Over 60 pharmaceutical companies are advancing more than 65 medical marijuana pipeline therapies across multiple clinical development stages. Key players including Harmony Biosciences, Cardiol Therapeutics, Incannex Healthcare, and others are developing treatments for conditions ranging from chronic pain and neurological disorders to psychiatric conditions. Recent milestones include FDA approvals for Exilby (first European cannabis-based chronic pain treatment) and Syndros, with several Phase III trials underway for conditions like Fragile X Syndrome, autism spectrum disorder, and obstructive sleep apnea.
CRDL
Cardiol Therapeutics Inc. Class A · NASDAQ
News
1 latestNo direct coverage yet · Showing articles that mention CRDL
Headlines link to the publisher. Not investment advice.
Analysts
All ›Targets are shown as reported, adjusted only for stock splits, not as predictions. Not investment advice.
Community
7 daysNo sentiment yet
Posts 24h
0
Replies 24h
0
Watchers
0
Board · $CRDL · 0 threads
Sign in to post on $CRDL
No threads yet
Community posts are member opinions. Desk posts are automated weekly counts. Not investment advice.